Mannan, A Potential Therapeutic for Asthma

甘露聚糖，一种治疗哮喘的潜在药物

基本信息

批准号：
7591462
负责人：
DUKHEE Betty LEW
金额：
$ 11.18万
依托单位：
CUMBERLAND PHARMACEUTICALS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-02-01 至 2011-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7591462
关键词：
Address Adverse effects Airway Resistance Allergic Asthma Breathing Carbohydrates Cell Culture System Childhood Asthma Clinical Trials Disease Dose Emerging Technologies Goals Human Hyperplasia Hypersensitivity Immunology Immunomodulators In Vitro Inflammation Inflammatory Intranasal Administration Knowledge Laboratories Lead Mannans Medicine Modeling Mus Oral Oral Administration Ovalbumin Pharmacologic Substance Phase Powder dose form Rhinitis Route Saccharomyces Saccharomyces cerevisiae Small Business Technology Transfer Research Smooth Muscle Smooth Muscle Myocytes Solutions Source System Tennessee Testing Therapeutic Time Toxic effect Transgenic Organisms Universities airway hyperresponsiveness airway inflammation aqueous asthmatic patient base college commercial application in vivo mannose receptor methacholine mouse model muscle hypertrophy novel pediatric department pre-clinical prebiotics preclinical study prevent public health relevance respiratory respiratory smooth muscle

项目摘要

DESCRIPTION (provided by applicant): The long-term goal of this application is to develop mannan derived from Baker's yeast as asthma therapy. The limitations of currently available immunomodulators are their toxicity at higher doses and the lack of beneficial effect on airway smooth muscle (ASM) remodeling and therefore, new adjunctive therapeutics are needed. Initial findings in the P.I.'s laboratory have shown that mannan from S. cerevisiae, a carbohydrate-based prebiotic polymannose agent, inhibits airway inflammation, hyperreactivity (AHR) and ASM remodeling. Our central hypothesis is that mannan from S. cerevisiae is a novel class of immunomodulator that suppresses ASM remodeling. Studies are proposed 1) to determine the optimum dose and dose timing of mannan administered intranasally. 2) to determine the optimum dose and dose timining of mannan administered orally. The University of Tennessee College of Medicine Department of Pediatric Allergy/Immunology and Cumberland Emerging Technologies Inc (CET), an affiliate of Cumberland Pharmaceuticals Inc (CPI), are collaborating to identify and develop promising pharmaceutical therapies for treating and preventing asthma. The P.I. will conduct preclinical studies outlined in the proposal and CET will develop the product for the preclinical and clinical trials. The knowledge gained from these studies will provide a novel class of adjuctive asthma therapy that will modulate ASM remodeling and will lead to a unique intranasal and oral products that will benefit asthmatics and patients with other related diseases. PUBLIC HEALTH RELEVANCE: Our central hypothesis is that mannan from S. cerevisiae is a novel class of immunomodulator that suppresses ASM remodeling. The long-term goal of this application is to develop mannan derived from Baker's yeast as asthma therapy.

描述（由申请人提供）：本申请的长期目标是开发以贝克酵母作为哮喘治疗的曼南。当前可用的免疫调节剂的局限性是它们在较高剂量时的毒性，并且对气道平滑肌（ASM）重塑缺乏有益作用，因此需要新的辅助治疗剂。 P.I.实验室的初步发现表明，酿酒酵母的曼南是一种基于碳水化合物的益生元聚甘露糖剂，抑制气道炎症，过度反应性（AHR）和ASM重塑。我们的中心假设是，酿酒酵母的曼南是一种新型的免疫调节剂，可抑制ASM重塑。提出了研究1）确定鼻内施用的曼南的最佳剂量和剂量时间。 2）确定口服曼南的最佳剂量和剂量弄元。田纳西大学医学院儿科过敏/免疫学系与坎伯兰新兴技术公司（CET），Cumberland Pharmaceuticals Inc（CPI）的分支机构，正在合作识别和开发有希望的药物治疗和预防哮喘的有前途的药物疗法。 P.I.将在提案中概述的临床前研究，CET将开发用于临床前和临床试验的产品。从这些研究中获得的知识将提供一类新型的检查性哮喘治疗，该疗法将调节ASM重塑，并导致独特的鼻内和口服产物，这些产品将使哮喘患者和患有其他相关疾病的患者受益。公共卫生相关性：我们的中心假设是，酿酒酵母的曼南是一种新颖的免疫调节剂，可抑制ASM重塑。该应用程序的长期目标是开发从贝克酵母作为哮喘治疗的曼南。

项目成果

期刊论文数量（1）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Beneficial Effects of Prebiotic Saccharomyces cerevisiae Mannan on Allergic Asthma Mouse Models.

DOI：
10.1155/2017/3432701
发表时间：
2017
期刊：
Journal of immunology research
影响因子：
4.1
作者：
Lew DB;Michael CF;Overbeck T;Robinson WS;Rohman EL;Lehman JM;Patel JK;Eiseman B;LeMessurier KS;Samarasinghe AE;Gaber MW
通讯作者：
Gaber MW